Charles Schwab Investment Management Inc. Sells 25,227 Shares of Zoetis Inc. (NYSE:ZTS)

Charles Schwab Investment Management Inc. trimmed its stake in shares of Zoetis Inc. (NYSE:ZTS) by 0.8% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 3,311,293 shares of the company’s stock after selling 25,227 shares during the quarter. Charles Schwab Investment Management Inc.’s holdings in Zoetis were worth $566,342,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also bought and sold shares of the stock. Citigroup Inc. grew its position in Zoetis by 5.7% during the 2nd quarter. Citigroup Inc. now owns 512,520 shares of the company’s stock worth $88,261,000 after acquiring an additional 27,505 shares during the last quarter. Beverly Hills Private Wealth LLC bought a new stake in shares of Zoetis in the 2nd quarter worth approximately $3,104,000. EULAV Asset Management grew its position in shares of Zoetis by 116.7% in the 2nd quarter. EULAV Asset Management now owns 65,000 shares of the company’s stock worth $11,194,000 after buying an additional 35,000 shares during the last quarter. Burney Co. grew its position in shares of Zoetis by 78.7% in the 2nd quarter. Burney Co. now owns 3,949 shares of the company’s stock worth $680,000 after buying an additional 1,739 shares during the last quarter. Finally, Dimensional Fund Advisors LP grew its position in shares of Zoetis by 2.2% in the 2nd quarter. Dimensional Fund Advisors LP now owns 1,610,380 shares of the company’s stock worth $277,326,000 after buying an additional 34,235 shares during the last quarter. 89.47% of the stock is currently owned by institutional investors.

Zoetis Trading Up 1.1 %

ZTS opened at $174.62 on Thursday. The stock has a market cap of $80.17 billion, a PE ratio of 35.49, a PEG ratio of 2.72 and a beta of 0.83. The company has a quick ratio of 2.16, a current ratio of 3.87 and a debt-to-equity ratio of 1.29. The business has a 50 day moving average of $172.30 and a 200-day moving average of $175.70. Zoetis Inc. has a 52 week low of $140.76 and a 52 week high of $194.99.

Zoetis Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, December 1st. Stockholders of record on Wednesday, November 1st will be paid a $0.375 dividend. This represents a $1.50 dividend on an annualized basis and a dividend yield of 0.86%. The ex-dividend date is Tuesday, October 31st. Zoetis’s payout ratio is presently 30.49%.

Insider Buying and Selling at Zoetis

In other Zoetis news, CEO Kristin C. Peck sold 13,000 shares of the business’s stock in a transaction on Tuesday, August 22nd. The stock was sold at an average price of $179.97, for a total value of $2,339,610.00. Following the sale, the chief executive officer now directly owns 56,843 shares of the company’s stock, valued at $10,230,034.71. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In other Zoetis news, CEO Kristin C. Peck sold 13,000 shares of the business’s stock in a transaction on Tuesday, August 22nd. The stock was sold at an average price of $179.97, for a total value of $2,339,610.00. Following the sale, the chief executive officer now directly owns 56,843 shares of the company’s stock, valued at $10,230,034.71. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Roxanne Lagano sold 923 shares of the business’s stock in a transaction on Wednesday, October 18th. The stock was sold at an average price of $172.92, for a total value of $159,605.16. Following the completion of the sale, the executive vice president now directly owns 23,588 shares in the company, valued at $4,078,836.96. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 25,674 shares of company stock worth $4,627,465. 0.15% of the stock is owned by insiders.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on ZTS shares. Stifel Nicolaus cut their price objective on Zoetis from $205.00 to $195.00 and set a “buy” rating on the stock in a research report on Monday, October 30th. The Goldman Sachs Group lifted their price objective on Zoetis from $204.00 to $213.00 and gave the stock a “buy” rating in a research report on Wednesday, August 9th. Piper Sandler lifted their price objective on Zoetis from $210.00 to $215.00 and gave the stock an “overweight” rating in a research report on Monday, November 6th. HSBC started coverage on Zoetis in a research report on Wednesday, September 6th. They issued a “buy” rating and a $230.00 price objective on the stock. Finally, StockNews.com lowered Zoetis from a “strong-buy” rating to a “buy” rating in a research report on Sunday, October 8th. Seven analysts have rated the stock with a buy rating, According to data from MarketBeat, Zoetis has an average rating of “Buy” and a consensus target price of $216.29.

Zoetis Company Profile

Zoetis Inc discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.